Small interfering RNA against the 2C genomic region of coxsackievirus B3 exerts potential antiviral effects in permissive HeLa cells

Virus Research

Volumn 163, Issue 1, 2012, Pages 183-189

  Luan, Ying ^a   Dai, Hai Li ^a   Yang, Dan ^a   Zhu, Lin ^a   Gao, Tie Lei ^a   Shao, Hong Jiang ^a   Peng, Xue ^a   Jin, Zhan Feng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Coxsackievirus B3; RNA interference; Small interfering RNA

Indexed keywords

SMALL INTERFERING RNA; SMALL INTERFERING RNA 1; SMALL INTERFERING RNA 10; SMALL INTERFERING RNA 11; SMALL INTERFERING RNA 2; SMALL INTERFERING RNA 3; SMALL INTERFERING RNA 4; SMALL INTERFERING RNA 5; SMALL INTERFERING RNA 6; SMALL INTERFERING RNA 7; SMALL INTERFERING RNA 8; SMALL INTERFERING RNA 9; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOPATHOGENIC EFFECT; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION; WESTERN BLOTTING;

ANTIVIRAL AGENTS; BIOLOGICAL AGENTS; CARRIER PROTEINS; CELL SURVIVAL; CYTOPATHOGENIC EFFECT, VIRAL; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

COXSACKIEVIRUS;

EID: 84855613808     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.09.016     Document Type: Article

References (37)

1. Ahn J., Joo C.H., Seo I., Kim D., Hong H.N., Kim Y.K., Lee H. Characteristics of apoptotic cell death induced by coxsackievirus B in permissive Vero cells. Intervirology 2003, 46(4):245-251.
2. Ahn J., Jun E.S., Lee H.S., Yoon S.Y., Kim D., Joo C.H., Kim Y.K., Lee H. A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J. Virol. 2005, 79(13):8620-8624.
3. Bauer S., Gottesman G., Sirota L., Litmanovitz I., Ashkenazi S., Levi I. Severe Coxsackie virus B infection in preterm newborns treated with pleconaril. Eur. J. Pediatr. 2002, 161(9):491-493.
4. Bhuyan P.K., Kariko K., Capodici J., Lubinski J., Hook L.M., Friedman H.M., Weissman D. Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. J. Virol. 2004, 78(19):10276-10281.
5. Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 2003, 34(3):263-264.
6. Cullen B.R. RNA interference: antiviral defense and genetic tool. Nat. Immunol. 2002, 3(7):597-599.
7. Dunn J.J., Chapman N.M., Tracy S., Romero J.R. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region. J. Virol. 2000, 74(10):4787-4794.
8. Dykxhoorn D.M., Novina C.D., Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 2003, 4(6):457-467.
9. Elbashir S.M., Lendeckel W., Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001, 15(2):188-200.
10. Feldman A.M., McNamara D. Myocarditis. N. Engl. J. Med. 2000, 343(19):1388-1398.
11. Feuer R., Mena I., Pagarigan R.R., Harkins S., Hassett D.E., Whitton J.L. Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. Am. J. Pathol. 2003, 163(4):1379-1393.
12. Gay R.T., Belisle S., Beck M.A., Meydani S.N. An aged host promotes the evolution of avirulent coxsackievirus into a virulent strain. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(37):13825-13830.
13. Heidel J.D., Hu S., Liu X.F., Triche T.J., Davis M.E. Lack of interferon response in animals to naked siRNAs. Nat. Biotechnol. 2004, 22(12):1579-1582.
14. Heim A., Canu A., Kirschner P., Simon T., Mall G., Hofschneider P.H., Kandolf R. Synergistic interaction of interferon-beta and interferon-gamma in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 1992, 166(5):958-965.
15. Holen T., Amarzguioui M., Wiiger M.T., Babaie E., Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. 2002, 30(8):1757-1766.
16. Jun E.J., Nam Y.R., Ahn J., Tchah H., Joo C.H., Jee Y., Kim Y.K., Lee H. Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24. Biochem. Biophys. Res. Commun. 2008, 376(2):389-394.
17. Kim J.Y., Chung S.K., Hwang H.Y., Kim H., Kim J.H., Nam J.H., Park S.I. Expression of short hairpin RNAs against the coxsackievirus B3 exerts potential antiviral effects in Cos-7 cells and in mice. Virus Res. 2007, 125(1):9-13.
18. Kim Y.J., Ahn J., Jeung S.Y., Kim D.S., Na H.N., Cho Y.J., Yun S.H., Jee Y., Jeon E.S., Lee H., Nam J.H. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model. Virus Genes 2008, 36(1):141-146.
19. Klingel K., McManus B.M., Kandolf R. Enterovirus-infected immune cells of spleen and lymph nodes in the murine model of chronic myocarditis: a role in pathogenesis?. Eur. Heart J. 1995, 16(Suppl O):42-45.
20. Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 1996, 70(11):7811-7818.
21. Lang C., Sauter M., Szalay G., Racchi G., Grassi G., Rainaldi G., Mercatanti A., Lang F., Kandolf R., Klingel K. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J. Mol. Med. 2008, 86(1):49-60.
22. Lee H.S., Ahn J., Jun E.J., Yang S., Joo C.H., Kim Y.K., Lee H. A novel program to design siRNAs simultaneously effective to highly variable virus genomes. Biochem. Biophys. Res. Commun. 2009, 384(4):431-435.
23. Maisch B., Ristic A.D., Hufnagel G., Pankuweit S. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc. Pathol. 2002, 11(2):112-122.
24. Merl S., Michaelis C., Jaschke B., Vorpahl M., Seidl S., Wessely R. Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 2005, 111(13):1583-1592.
25. Merl S., Wessely R. Anti-coxsackieviral efficacy of RNA interference is highly dependent on genomic target selection and emergence of escape mutants. Oligonucleotides 2007, 17(1):44-53.
26. Norder H., De Palma A.M., Selisko B., Costenaro L., Papageorgiou N., Arnan C., Coutard B., Lantez V., De Lamballerie X., Baronti C., Sola M., Tan J., Neyts J., Canard B., Coll M., Gorbalenya A.E., Hilgenfeld R. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 2011, 89(3):204-218.
27. Racchi G., Klingel K., Kandolf R., Grassi G. Targeting of protease 2A genome by single and multiple siRNAs as a strategy to impair CVB3 life cycle in permissive HeLa cells. Methods Find. Exp. Clin. Pharmacol. 2009, 31(2):63-70.
28. Ren X.R., Zhou L.J., Luo G.B., Lin B., Xu A. Inhibition of hepatitis B virus replication in 2.2.15 cells by expressed shRNA. J. Viral Hepat. 2005, 12(3):236-242.
29. Rossi J.J. RNAi as a treatment for HIV-1 infection. Biotechniques 2006, Suppl.:25-29.
30. Sim A.C., Luhur A., Tan T.M., Chow V.T., Poh C.L. RNA interference against enterovirus 71 infection. Virology 2005, 341(1):72-79.
31. Tomari Y., Matranga C., Haley B., Martinez N., Zamore P.D. A protein sensor for siRNA asymmetry. Science 2004, 306(5700):1377-1380.
32. Wang A., Cheung P.K., Zhang H., Carthy C.M., Bohunek L., Wilson J.E., McManus B.M., Yang D. Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides. Antimicrob. Agents Chemother. 2001, 45(4):1043-1052.
33. Wessely R., Klingel K., Knowlton K.U., Kandolf R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 2001, 103(5):756-761.
34. Xu Y., Zhang H.Y., Thormeyer D., Larsson O., Du Q., Elmen J., Wahlestedt C., Liang Z. Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. Biochem. Biophys. Res. Commun. 2003, 306(3):712-717.
35. Yokota T., Sakamoto N., Enomoto N., Tanabe Y., Miyagishi M., Maekawa S., Yi L., Kurosaki M., Taira K., Watanabe M., Mizusawa H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003, 4(6):602-608.
36. Yuan J., Cheung P.K., Zhang H.M., Chau D., Yang D. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J. Virol. 2005, 79(4):2151-2159.
37. Zaragoza C., Ocampo C.J., Saura M., Bao C., Leppo M., Lafond-Walker A., Thiemann D.R., Hruban R., Lowenstein C.J. Inducible nitric oxide synthase protection against coxsackievirus pancreatitis. J. Immunol. 1999, 163(10):5497-5504.